The investment objective of the scheme is to provide returns that before expenses, closely correspond to the total returns of securities as represented by Nifty Healthcare TRI, subject to tracking errors. However, the performance of scheme may differ from that of the underlying index due to tracking error.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| ETFs | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -6.38% | -4.45% | 7.53% | 9.15% | 4.95% | 3.21% | 18.01% | 17.82% | 0% | N/A | 12.85% |
| Category returns | -2.99% | -4.52% | -3.02% | -5.03% | -4.77% | -2.03% | 9% | 10.98% | 7.45% | 11.5% | N/A |
| Absolute returns | -6.38% | -4.45% | 7.53% | 9.15% | 4.95% | 6.54% | 64.4% | 92.8% | 0% | N/A | 82.97% |
| Rank within category | 249/268 | 93/252 | 9/241 | 13/228 | 17/207 | 28/162 | 8/134 | 11/112 | 75/81 | N/A | N/A |
| ETFs | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Yearly returns | N/A | -10.15% | 33.82% | 41.77% | -1.71% | 6.61% |
| Q1 returns | N/A | -5.31% | -4.51% | 14.14% | -8.38% | -2.86% |
| Q2 returns | N/A | -11.27% | 17.25% | 4.25% | 5.78% | 13.69% |
| Q3 returns | N/A | 9.77% | 9.2% | 17.62% | -2.01% | 0.14% |
| Q4 returns | N/A | -2.57% | 9.45% | 1.29% | 3.51% | -3.6% |
| Alpha | -0.0038264 |
| Beta | 1.0046 |
| Sharpe Ratio | 0.271462 |
| Sortino Ratio | 0.587476 |
| R-Squared | 0.9967 |
| Tracking Error | 0.1063 |
| Downside Risk | 17.2167 |
| Std. Deviation (Annualised) | 14.238 |
| ETFs | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | -7.16% | -4.01% | 10.11% | 12.75% | 6.7% | 19.48% | N/A | N/A | 19.41% | 44.40 | 0.36 | 0.30 | Very High |
| Nippon India Nifty Pharma ETF | -4.12% | -0.09% | 14.11% | 16.17% | 15.52% | 19.28% | 12.79% | N/A | 12.07% | 1,736.44 | 0.23 | 0.30 | Very High |
| Motilal Oswal BSE Enhanced Value ETF | -3.37% | -6.03% | -9.38% | -9.5% | -0.01% | 18.7% | N/A | N/A | 26.28% | 146.61 | 0.43 | 0.20 | Very High |
| DSP Nifty PSU Bank ETF | -0.29% | -1.08% | -5.84% | -7.11% | 9.24% | 18.66% | N/A | N/A | 20.49% | 1,434.17 | 0.16 | 0.15 | Very High |
| ICICI Prudential Nifty PSU Bank ETF | -0.32% | -1.15% | -6.01% | -7.33% | 8.91% | 18.53% | N/A | N/A | 26.2% | 118.61 | 0.41 | 0.15 | Very High |
| Nippon India ETF Nifty PSU Bank BeES | -0.32% | -1.17% | -6.04% | -7.39% | 8.81% | 18.35% | 25.56% | 10.01% | 6.93% | 3,932.00 | 0.51 | 0.14 | Very High |
| Kotak Nifty PSU Bank ETF | -0.32% | -1.17% | -6.06% | -7.4% | 8.79% | 18.33% | 25.56% | 9.94% | 6.36% | 2,490.74 | 0.51 | 0.14 | Very High |
| Aditya Birla Sun Life Nifty Healthcare ETF Current | -6.38% | -4.45% | 7.53% | 9.15% | 4.95% | 18.01% | 0% | N/A | 12.85% | 74.67 | 0.20 | 0.27 | Very High |
| ICICI Prudential Nifty Healthcare ETF | -6.38% | -4.44% | 7.56% | 9.19% | 5% | 17.87% | 12.38% | N/A | 12.86% | 231.43 | 0.16 | 0.27 | Very High |
| CPSE Exchange Traded Scheme | -4.68% | -8.11% | -17.4% | -5.64% | -6.14% | 17.73% | 22.49% | 13.23% | 13.75% | 18,645.20 | 0.08 | 0.19 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 17.00% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 10.46% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 7.45% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.81% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.69% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.64% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.26% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 6.11% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.35% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.08% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 3.54% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.10% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.77% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.54% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.50% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.36% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.28% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.04% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 1.76% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.22% |
| TREPS | Cash & Cash Equivalents and Net Assets | 0.71% | |
| Net Receivable / Payable | Cash & Cash Equivalents and Net Assets | -0.69% | |
| Total | 100.00% | ||
Ms. Priya Sridhar has an experience of over 13 years in dealing activities in equity segment including ETFs and Index Funds. Prior to joining ABSLAMC, she was associated with ICICI Prudential Asset Management Company as Fund Manager and Dealer - Passive Funds. She has also worked with ITI Asset Management Limited as Senior Dealer -Equity and Arbitrage Funds.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
